FDA-cleared profile

Rapid RV/LV

iSchema View Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Adjunctive measurement of the RV/LV ratio as a clinical metric used by medical professionals to quantify severity of right-heart strain in adults evaluated with CTPA; the annotated measurements support, but do not replace, clinical assessment.

Clinical role
Adjunctive quantitative aid within the integrated Rapid Platform; results are not intended for stand-alone clinical decision-making and do not preclude clinical assessment of the CTPA case.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The labeled population is adults with volumetric CTPA. Rapid RV/LV is not intended for stand-alone clinical decision-making and must not preclude clinical assessment. FDA validation used 124 cases with expert ground truth and scanners from GE, Philips, Toshiba and Siemens; performance outside the submitted conditions was not established here.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive measurement of the RV/LV ratio as a clinical metric used by medical professionals to quantify severity of right-heart strain in adults evaluated with CTPA; the annotated measurements support, but do not replace, clinical assessment.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Adult volumetric CTPA acquisitions provided as DICOM images; the FDA comparison identifies non-gated CT angiography images as the input requirement.
  • Who uses it?Intended users: Medical professionals who use RV/LV ratio as a clinical metric quantifying the severity of right-heart strain.
  • What does the software produce?Output: Annotated images with the ventricular measurement locations, quantitative maximal right- and left-ventricular diameters, the RV/LV ratio, a visual color-overlay result, a text report and a JSON text file containing quantitative measurement results; DICOM Secondary Capture is also described.
  • What is its most important limitation?Key limitation: The labeled population is adults with volumetric CTPA. Rapid RV/LV is not intended for stand-alone clinical decision-making and must not preclude clinical assessment. FDA validation used 124 cases with expert ground truth and scanners from GE, Philips, Toshiba and Siemens; performance outside the submitted conditions was not established here.

Clinical takeaway. Clinical role: Adjunctive measurement of the RV/LV ratio as a clinical metric used by medical professionals to quantify severity of right-heart strain in adults evaluated with CTPA; the annotated measurements support, but do not replace, clinical assessment.

Evidence takeaway. Evidence from the reviewed source record: Final FDA validation included 124 CTPA cases with ground truth established by three experts. The reported average slope was 1.1, average intercept -0.2, Bland-Altman mean bias 0.023 and mean absolute error 3.8 mm; the source text reports the associated confidence intervals, including malformed intercept-CI formatting.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive measurement of the RV/LV ratio as a clinical metric used by medical professionals to quantify severity of right-heart strain in adults evaluated with CTPA; the annotated measurements support, but do not replace, clinical assessment.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Adjunctive quantitative aid within the integrated Rapid Platform; results are not intended for stand-alone clinical decision-making and do not preclude clinical assessment of the CTPA case.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult volumetric CTPA acquisitions provided as DICOM images; the FDA comparison identifies non-gated CT angiography images as the input requirement.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Annotated images with the ventricular measurement locations, quantitative maximal right- and left-ventricular diameters, the RV/LV ratio, a visual color-overlay result, a text report and a JSON text file containing quantitative measurement results; DICOM Secondary Capture is also described.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Medical facilities evaluating adults with volumetric CTPA for suspected or known cardiopulmonary disease, with professional review of the CTPA case.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Medical professionals who use RV/LV ratio as a clinical metric quantifying the severity of right-heart strain.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The labeled population is adults with volumetric CTPA. Rapid RV/LV is not intended for stand-alone clinical decision-making and must not preclude clinical assessment. FDA validation used 124 cases with expert ground truth and scanners from GE, Philips, Toshiba and Siemens; performance outside the submitted conditions was not established here.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
Final FDA validation included 124 CTPA cases with ground truth established by three experts. The reported average slope was 1.1, average intercept -0.2, Bland-Altman mean bias 0.023 and mean absolute error 3.8 mm; the source text reports the associated confidence intervals, including malformed intercept-CI formatting.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Final FDA validation included 124 CTPA cases with ground truth established by three experts. The reported average slope was 1.1, average intercept -0.2, Bland-Altman mean bias 0.023 and mean absolute error 3.8 mm; the source text reports the associated confidence intervals, including malformed intercept-CI formatting.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The FDA endpoints are continuous ventricular measurements and agreement statistics, not disease-detection sensitivity.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The FDA endpoints are continuous ventricular measurements and agreement statistics, not disease-detection specificity.

Validation regression slope

1.1 slope

  • EndpointRegression of Rapid RV/LV measurement against expert ground truth
  • Population124 CTPA cases with ground truth established by three experts
  • Tested versionRapid RV/LV configuration submitted in K223396

Validation regression intercept

-0.2 ratio units

  • EndpointRegression intercept for Rapid RV/LV measurement against expert ground truth
  • Population124 CTPA cases with ground truth established by three experts
  • Tested versionRapid RV/LV configuration submitted in K223396

Bland-Altman mean bias

0.023 RV/LV ratio units

  • EndpointMean bias between Rapid RV/LV and expert measurements
  • Population124 CTPA cases with ground truth established by three experts
  • Tested versionRapid RV/LV configuration submitted in K223396

Mean absolute error

3.8 mm

  • EndpointMean absolute error between Rapid RV/LV and expert ventricular measurements
  • Population124 CTPA cases with ground truth established by three experts
  • Tested versionRapid RV/LV configuration submitted in K223396

Rapid RV/LV final performance validation

  • DesignStandalone performance validation comparing automated ventricular measurements with ground truth established by three experts, including regression and Bland-Altman endpoints.
  • Population124 CTPA cases; the FDA summary reports a 44% male and 56% female split, ages 26-93, with GE, Philips, Toshiba and Siemens scanners.
  • Scopeexact submission
  • Tested versionRapid RV/LV configuration submitted in K223396
  • Samplen=124
  • IndependenceSponsor or vendor study

K223396

The FDA source prints a malformed confidence-interval expression for the intercept; the reported intercept value is preserved without reconstructing or recalculating that interval.

Rapid RV/LV algorithm development dataset

  • DesignAlgorithm development dataset described in the FDA 510(k) summary; this is not the final clinical performance validation cohort.
  • Population516 CTPA cases from multiple sites and Siemens, GE, Toshiba and Philips scanners; the submission describes an 80% validation and 20% training split.
  • Scopeexact submission
  • Tested versionRapid RV/LV configuration submitted in K223396
  • Samplen=516
  • IndependenceSponsor or vendor study

K223396

The source wording for the development split is retained; this dataset is not used as a substitute for the 124-case final validation.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult volumetric CTPA acquisitions provided as DICOM images; the FDA comparison identifies non-gated CT angiography images as the input requirement.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K223396: Rapid RV/LV

  2. Routing

    Source context, not route validation: The module operates within the integrated Rapid Platform, accepts CTPA DICOM, uses a command-line interface and provides reports, DICOM Secondary Capture and JSON quantitative output for downstream review or integration.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K223396: Rapid RV/LV

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA summary establishes Rapid Platform and command-line integration but does not establish the current exact K223396 hosting model.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 ·

  4. Returned objects

    Source context, not route validation: Annotated images with the ventricular measurement locations, quantitative maximal right- and left-ventricular diameters, the RV/LV ratio, a visual color-overlay result, a text report and a JSON text file containing quantitative measurement results; DICOM Secondary Capture is also described.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K223396: Rapid RV/LV

  5. Viewer/worklist/report

    Unresolved route: Annotated images with the ventricular measurement locations, quantitative maximal right- and left-ventricular diameters, the RV/LV ratio, a visual color-overlay result, a text report and a JSON text file containing quantitative measurement results; DICOM Secondary Capture is also described.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K223396: Rapid RV/LV

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The module operates within the integrated Rapid Platform, accepts CTPA DICOM, uses a command-line interface and provides reports, DICOM Secondary Capture and JSON quantitative output for downstream review or integration.
  • Exact FDA submission
  • Checked 2026-09-07
Security
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
  • Vendor-wide
  • Checked 2026-09-07

This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.

Monitoring
RapidAI's security and compliance one-pager (Rev 8, published by iSchemaView, Inc.) states continuous infrastructure monitoring and system telemetry to detect operational anomalies in real time, plus a formal incident response and escalation framework with defined communication protocols.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. No certificate or audit report was read; the one-pager names the RapidAI platform generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Integrated Rapid Platform and DICOM outputs

The cleared module operates within the integrated Rapid Platform, accepts CTPA DICOM through a command-line interface and produces annotated images, reports, DICOM Secondary Capture and JSON quantitative measurement results.

exact submission · checked 2026-09-07

Family PE workflow and care-team communication

RapidAI's current PE page lists Rapid PE RV/LV as a PE solution and describes bringing AI results, source imaging and clinical data into one platform, with EHR integration, care-team communication and analytics described at the family level.

product family · checked 2026-09-07

The current family page does not establish exact K223396 release, hosting, connector, price or performance terms.

Vendor-wide security and compliance documentation

RapidAI's current security one-pager lists encryption at rest and in transit, role-based access control, monitoring/logging, secure development practices and a vendor-stated compliance framework for its platform portfolio.

vendor wide · checked 2026-09-07

This is vendor-supplied portfolio context and is not independent confirmation of exact K223396 controls or contractual scope.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223396
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-02-01
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
20Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened. The broad Rapid RV/LV query returned 20 PubMed identifiers without exact K223396 linkage established in metadata; no full paper was reviewed and no candidate is promoted as product evidence. The current discovery snapshot contains 20 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor technical documentation, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for the exact K223396 configuration was reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Rapid CTA 360 RapidAI reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. RapidAI's reimbursement page lists NTAP for Rapid LVO (FY2021-2022 rules); it does not name this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Deployment: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The exact FDA summary establishes Rapid Platform and command-line integration but does not establish the current exact K223396 hosting model.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K223396: Rapid RV/LV

    U.S. Food and Drug Administration - Published 2023-02-01 - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rapid RV/LV model card (K223396)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RapidAI cardiac and vascular solutions

    RapidAI - Accessed 2026-09-08

    Scope: productFamily, clinicalWorkflow, implementationCapabilities

  8. RapidAI security and compliance one-pager

    RapidAI - Accessed 2026-09-08

    Scope: vendorWideSecurity, deployment, implementationCapabilities

  9. RapidAI security and compliance one-pager (Rev 8)

    iSchemaView, Inc. (RapidAI) - Accessed 2026-10-27

    Scope: security, monitoring

Research history

  1. K223396 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history